RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
JOURNAL OF CLINICAL ONCOLOGY
Collezione ASL Biella

Items : 14

Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in Journal of Clinical Oncology

2025
ASL Biella

Heitz F; Willmott L; Mathiesen HF; Gilbert L; Mendivil A; Zavallone L; Stuckey A; Novák Z; Diaz JP; Thijs A; Teneriello M; Edelson M; Holloway RW; Armstrong AJ; Buttin B; Powell MA; Westermayer B; Shen Q; Mirza MR; Ring K;

A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS trial. in Journal of Clinical Oncology

2025
ASL Biella

Montagut CO; Tamberi S; Leone F; Libertini M; Negri F; Pastorino A; Siena S; Fenocchio E; Gennari A; Mandala M; Santoro A; Tarazona N; Elez E; Sartore-Bianchi A; Stintzing S; Muñoz S; Sibilio A; Silvestri Y; Lazzari L; Marsoni S;

Breast cancer in patients with Lynch syndrome: A single institution retrospective analysis in Journal of Clinical Oncology

2023
ASL Biella

Miano ST; Petrioli R; Martellucci I; Montagnani F; Civitelli S; Francini G; Giuffrida D; Mencarelli MA; Renieri A; Prestifilippo A; Francini E;

Safety and feasibility of a randomized controlled trial testing a personalized exercise program in patients with cancer: The CHOiCE trial in Journal of Clinical Oncology

2023
ASL Biella

Pilotto S; Scrivano FGG; Borsati A; Tregnago D; Trestini I; Belluomini L; Riva S; Sposito M; Insolda J; Valentini M; Bria E; Schena F; Milella M; Lanza M; Avancini A;

Intensive versus minimalist followup in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study-NCT00916708) in Journal of Clinical Oncology

2021
ASL Biella

Zola P; Ciccone G; Piovano E; Fuso L; Peirano E; Di Cuonzo D; Perrone AM; Mandato VD; Zavallone L; Chiudinelli F; Berretta R; Loda S; Menada MV; Greggi S; Adorni M; Busato E; Marinaccio M; Comerci G; Fambrini M; Ferrero A;

Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database in Journal of Clinical Oncology

2020
ASL Biella

Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Cigliola A; Moreno I; Rubio J; Crivelli F; Shaw G; Petrioli R; Bengala C; Francini G; Foncillas JG; Sweeney C; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC;

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: Retrospective analysis of clinical outcomes in Journal of Clinical Oncology

2020
ASL Biella

Giannone G; Scotto G; De Giorgi U; Farolfi A; Katsaros D; Borella F; Ferrero A; Villa M; Tuninetti V; Ghisoni E; Turinetto M; Zavallone L; Aglietta M; Pasini B; Di Maio M; Valabrega G;

Early progression of disease (POD24) as survival predictor in MALT lymphoma in Journal of Clinical Oncology

2019
ASL Biella

Conconi A; Thieblemont C; Cascione L; Torri V; Kiesewetter B; Margiotta-Casaluci G; Gaidano G; Raderer M; Cavalli F; Lopez-Guillermo A; Johnson PWM; Zucca E;

2019
ASL Biella

Romano E; Poli R; Dumont C; Pietrogiovanna L; Vigan M; Servois V; Bidard F-C; Beaucaire-Danel S; Daniel C; Girard N; Hescot S; Savignoni A;

Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry in Journal of Clinical Oncology

2019
ASL Biella

Francini E; Montagnani F; Vitale NP; Alimohamed NS; Candilejo IM; Rosellini P; Gonzalez-Velez M; Rubio J; Zhang L; Shaw G; Crivelli F; Petrioli R; Bengala C; Francini G; Foncillas JG; Bryce AH; Sweeney C; Harshman LC; Lee-Ying R; Heng DYC;

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis in Journal of Clinical Oncology

2016
ASL Biella

Scartozzi M; Giampieri R; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Casula L; Cozzi L; Germano D; Puzzoni M; Loretelli C; Zagonel V; Labianca R; Frontini L; Cascinu S;

Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study in Journal of Clinical Oncology

2016
ASL Biella

Marmorino F; Cremolini C; Loupakis F; Barbara C; Dargenio F; Miraglio E; Masi G; Salvatore L; Marcucci L; Antonuzzo L; Chiara S; Banzi C; Schirripa M; Amoroso D; Bonetti A; Martignetti A; Paris M; Boni L; Tomcikova D; Falcone A;

Italian observational study in patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab based regimen (ObservEr study) in Journal of Clinical Oncology

2014
ASL Biella

Di Fabio F; Rosati G; Lolli IR; Ruggeri EM; Ciuffreda L; Ferrari D; Tumolo S; Rosti G; Tralongo P; Ferrara R; Alabiso O; Chiara S; Ianniello GP; Di Costanzo F; Frassoldati A; Iacono C; Clerico M; Pavesi L; Bernardo G; Pinto C;

Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A+C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study in Journal of Clinical Oncology

2013
ASL Biella

Roila F; Ballatori E; Fabi A; Fatigoni S; Chiara S; Ionta MT; Aieta M; Clerico M; Palladino MA; Indelli M; Garrone O; Bustreo S; Ruggeri B;